RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy

Bogani, Giorgio; Matteucci, Laura; Tamberi, Stefano; Ditto, Antonino; Sabatucci, Ilaria; Murgia, Ferdinando; Arcangeli, Valentina; Maltese, Giuseppa; Comerci, Giuseppe; Stefanetti, Marco; Sonetto, Cristina; Calareso, Giuseppina; Marchianò, Alfonso; Chiappa, Valentina; Lorusso, Domenica; Raspagliesi, Francesco

doi:10.1016/j.ejogrb.2019.04.007

Cited by 15 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When we measured the outcome as PFS and PFS2, responses to NACT allowed us to identify classes of patients whose outcomes differed. Many researchers have underlined the close relationship between responses to NACT measured using clinical and radiological criteria or specific histologic scores and outcome in patients with advanced tubo‐ovarian HGSC . In our series, responses to NACT significantly predicted the number of peritonectomy procedures needed to obtain cytoreduction.…”

Section: Discussionmentioning

confidence: 66%

Upfront debulking surgery versus interval debulking surgery for advanced tubo‐ovarian high‐grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC

Biacchi

Accarpio

Ansaloni

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background: Whether patients with advanced tubo-ovarian high-grade serous cancer (HGSC) fare better after upfront debulking surgery (UDS) or neoadjuvant chemotherapy with interval debulking surgery (NACT-IDS) remains controversial. Methods: We studied patients with HGSC who underwent UDS or NACT-IDS between July 2000 and December 2015, with peritonectomy procedures combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Clinical reports were included peritoneal cancer index (PCI), NACT responses, surgical complexity score (SCS), completeness of cytoreduction (CC), complete follow-up with timing, site, and treatment of recurrence. Outcome measures were morbidity, progression-free survival (PFS), PFS2, and overall survival during a mean 5-year follow-up. Results: A total of 34 patients (23.6%) underwent UDS and 110 (76.4%) NACT-IDS both combined with HIPEC. At a median 66.3-month follow-up, patients who underwent UDS or NACT-IDS had similar outcomes. NACT subgroup responses correlated with PCI, SCS, morbidity, and CC. Patients who underwent UDS had lower recurrence rates than those who responded partly or poorly to NACT (PFS, P < .04; PFS2, P < .01). Despite HIPEC, the peritoneal disease recurred in 42.5% of the overall patients. Conclusion: In patients with primary HGSC who undergo UDS or NACT-IDS, despite similar outcomes, peritonectomy procedures combined with HIPEC seem unable to prevent peritoneal recurrence. K E Y W O R D S HIPEC, interval debulking surgery, neoadjuvant chemotherapy, ovarian high-grade serous carcinoma, upfront debulking surgery Italian Peritoneal Surface Malignancies Oncoteam.

show abstract

Section: Discussionmentioning

confidence: 66%

Upfront debulking surgery versus interval debulking surgery for advanced tubo‐ovarian high‐grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC

Biacchi

Accarpio

Ansaloni

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Although relevant in clinical trials in patients with measurable lesions, imaging-based approaches relying on the tumor radiological response are still limited by the poor sensitivity of the current techniques for assessing peritoneal micro-infiltrative diseases frequently developed in ovarian cancer patients [45]. Conflicting outcomes were reported about the predictive value of the radiological response regarding the probability of complete IDS, or patient prognosis [46,47]. A recent analysis of the ICON-8 phase III trial dataset on 1566 patients confirmed that the radiological response assessed with the Response Evaluation Criteria in Solid Tumors (RECIST) was not an appropriate parameter to assess the efficacy of the neoadjuvant chemotherapy and predict the benefit from IDS [48].…”

Section: Indicators Of Tumor Primary Chemosensitivitymentioning

confidence: 99%

The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas

You

González-Martín

Lheureux

et al. 2021

Cancer Treatment Reviews

View full text Add to dashboard Cite

In patients with advanced ovarian carcinomas, the first-line treatment has historically relied on debulking surgery and platinum-based chemotherapy. If the major therapeutic/prognostic role of the surgery part is well understood, and integrated in disease-management algorithms, the impact of chemotherapy efficacy has been insufficiently addressed.This review describes the main indicators of the chemosensitivity reported in the literature (pathological response score & biomarkers; genomic alterations; DNA scars; imaging; and circulating tumor markers), and investigates the respective roles of the debulking surgery and tumor primary chemosensitivity relative to the success of the comprehensive medical-surgical treatment. The tumor primary chemosensitivity exhibits a major independent prognostic impact on the feasibility of complete interval debulking surgery after neoadjuvant chemotherapy, risk of subsequent platinum-resistant relapse, efficacy of subsequent maintenance therapies with bevacizumab or PARP inhibitors, progression-free survival, overall and long-term survival. While both the completeness of the surgery and the tumor primary chemosensitivity are undoubtedly major prognostic factors, the impact of the surgery may differ according to the primary chemosensitivity. This assumption raises a potential new concept: in patients with advanced ovarian carcinomas, the maximum tumor debulking should ideally be both biological (induced by systemic treatments) and physical (induced by surgery) for maximizing patient survival. Besides BRCA and HRD biomarkers, future trials and algorithms may integrate indicator(s) of the tumor primary chemosensitivity for guiding more subtly the surgical and medical management in first-line setting. Moreover, such a parameter would help in the development of novel approaches meant to reverse the resistance to chemotherapy and PARP inhibitors.

show abstract

“…Neoadjuvant chemotherapy is often used as an adjuvant intervention in the clinical treatment of breast cancer patients [ 12 , 13 ]. Before tumour resection or local chemoradiotherapy, the use of neoadjuvant chemotherapy reduces the lesion volume to a certain extent, and prevents the spread of cancer cells, resulting in a positive effect on subsequent treatments [ 14 , 15 ].…”

Section: Discussionmentioning

confidence: 99%

Potential of combination of DCE-MRI and DWI with serum CA125 and CA199 in evaluating effectiveness of neoadjuvant chemotherapy in breast cancer

et al. 2021

View full text Add to dashboard Cite

Background To determine the potential of the combination of DCE-MRI imaging method with DWI and serum CA125 and CA199 levels in the evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients. Methods Sixty-five breast cancer patients who received neoadjuvant chemotherapy in our hospital from April 2016 to April 2017 were selected as research subjects. The patients received 4 courses of neoadjuvant chemotherapy. Lesions were monitored using DCE-MRI and DWI, while ELISA was used to measure the serum expression levels of the tumour markers CA125 and CA199. The patients were divided into the remission group and ineffective group based on pathological diagnosis. Results There were significant differences in Kep, Ktrans, ADCmin, ADCmean, tumour volume, and serum levels of CA125 and CA199 in patients in the remission group, before and after neoadjuvant chemotherapy, and there were significant differences in post-chemotherapy values of these indexes between the remission group and the ineffective group (p < 0.01). Conclusion Combination of DCE-MRI diagnostic imaging with DWI can directly reflect the lesions in breast cancer patients after neoadjuvant chemotherapy. Serum levels of CA125 and CA199 levels are useful for evaluation of the impact of neoadjuvant chemotherapy on breast cancer patients, including risk of cancer cell metastasis and changes in some small lesions.

show abstract

RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy

Cited by 15 publications

References 14 publications

Upfront debulking surgery versus interval debulking surgery for advanced tubo‐ovarian high‐grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC

Upfront debulking surgery versus interval debulking surgery for advanced tubo‐ovarian high‐grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC

The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas

Potential of combination of DCE-MRI and DWI with serum CA125 and CA199 in evaluating effectiveness of neoadjuvant chemotherapy in breast cancer

Contact Info

Product

Resources

About